Saxagliptin Has a Promising Future

Saxagliptin Has a Promising Future

saxagliptinSaxagliptin, also known as the brand name Onglyza, is an oral diabetes medication for people with type 2 diabetes. Saxagliptin can help to control blood sugar levels, but is not a treatment for type 1 diabetes. Side effects of saxagliptin are mild, and may include a headache, stuffy or runny nose and a sore throat. Onglyza {saxagliptin} is available as film-coated tablets in strengths of 2.5 mg and 5 mg. What makes saxagliptin unique is that it helps to lower blood sugar spikes in a once daily safe and tolerable dose. A once a day dose alongside complementary diet and exercise is easy for patients to adhere to.

In a class of medications called dipeptidyl peptidase-4, or DPP-4 inhibitors saxagliptin works by increasing the amount of insulin produced by the body after meals when blood sugar is high. Saxagliptin is also the first diabetes drug to pass the FDA Cardiovascular Safety Review. The FDA determined in April of 2009 that saxagliptin did not put type 2 diabetes patients at an increased risk for cardiovascular events. In addition to cardiovascular safety, saxagliptin showed in clinical trials to significantly improve β-cell function, be weight neutral, and have a low risk for hypoglycemia.

Diabetes has an estimated prevalence of 220 million people worldwide and is expected to affect 440 million by the year 2030. These jaw-dropping statistics are leading research and development scientists to quickly begin developing new treatments for the estimated onslaught of cases. Spending on type 2 diabetes is also estimated to increase to $336 billion by the year 2034. The substantial increase in cases estimated over the next 20 years is surmised based upon evidence such as the advancing age of the population, reduced mortality rates and longer life spans of patients due to improved screening, and the increase in diabetes risk factors, specifically obesity and physical inactivity.

LGM Pharma supplies the Saxagliptin CAS# 361442-04-8 API for research and development purposes. Clients can be assured of quality API products and continuous support throughout the R&D process.

Products currently covered by valid US Patens are offered for R&D use in accordance with 35 USC 271(e)+A13(1). Any patent infringement and resulting liability is solely at buyer risk.

  • Share:

LGM Pharma Acquires CDMO

On July 27, 2020, LGM Pharma announced its acquisition of the formulation development and drug product contract manufacturing business of Nexgen Pharma, Inc. As a result, you will notice our new logo and visuals throughout the website. We’re working on updates to reflect the exciting, expanded CDMO capabilities and services we now can offer you.

This website uses cookies. By using our site, you agree to our terms of service